Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
NATCO is hoping that CDSCO would give emergency approval of this drug based on compassionate use for patients. Compassionate use approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug. The company is ready to launch the product this month if approval is given.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
